A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) (GZ402673-OBS13434) First published 24/09/2014 Last updated 21/02/2025 EU PAS number:EUPAS7346 Study Ongoing
Trial Transparency Team Trial Transparency Team contact-US@sanofi.comStudy contactcontact-US@sanofi.com